Colchicine therapy in children with FMF

Results Colchicine dose correlates with the genotype. It further increases linearly with an increase of age (1 18 years), body weight and body surface area. The correlation of colchicine dose with body surface revealed an average of 1 mg colchicine / 1 m. A high response rate in the CRP and the attack rate is shown both at time of therapy introduction (70% response CRP: 45.5% / attack frequency: 61.4%), as well as dose increases during the course of the disease (with an increase of 1.0 mg to 1 5 mg: 70% Response CRP: 32.1% / attack frequency: 42.3%). The severity of disease at diagnosis increases the likelihood of a dose raise in the first 12 months and 24 months after therapy introduction. An increase of classical inflammatory markers (CRP, SAA) and S100 proteins show a significant correlation to a dose increase in the following 12 or 24 months (p <0.05).